Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

Quantum Biopharma Ltd.

CIK 1771885Updated Nov 14, 2026

Name history
FSD Pharma Inc. · through Aug 15, 2024

QNTM price & chart

Provider market data

Loading TradingView…

CSE:QNTM on TradingView ↗

TradingView · Data may be delayed

About the company

Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (“Quantum” or the “Company”) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (“Lucid-MS”). Lucid-MS is a patented new chemical entity that has been shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

6-K · 2026-11-12 · 0001185185-26-005323

Company description from the cited filing.

Financials

FY 2025 · USD
Revenue— · FY 2025
Net income— · FY 2025
Assets—USD · FY 2025
Cash— · FY 2025
Operating income-15,302,374USD · FY 2025
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

Diluted EPS— · FY 2025

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemQ4 2025Q4 2024Q3 2025Q3 2024Q2 2025Q2 2024Q1 2025Q1 2024FY 2025FY 2024FY 2023FY 2022
Cash flows from operating activities:
Profit or LossUSD——-4,747,600
Source

6-K · 2025-11-06 · 0001185185-25-001635

2025-07-01 to 2025-09-30

-4,015,327
Source

6-K · 2025-11-06 · 0001185185-25-001635

2024-07-01 to 2024-09-30

-9,766,327
Source

6-K · 2025-08-07 · 0001185185-25-000906

2025-04-01 to 2025-06-30

-3,352,499
Source

6-K · 2025-08-07 · 0001185185-25-000906

2024-04-01 to 2024-06-30

-8,739,881
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

-2,091,425
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

———-23,606,828
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

Additional Financial Items
AdjustmentsForFinanceIncomeUSD——————-414,189
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

-548,547
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

-1,491,001
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

-4,663,014
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

663,698
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

7,431,656
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD——————-177,476
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

-1,049,365
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

1,178,497
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

———
AdjustmentsForSharebasedPaymentsUSD——————291,272
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

57,743
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

2,945,502
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

—16,702
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

1,531,258
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD———————————934,100
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

GeneralAndAdministrativeExpenseUSD———3,250,030
Source

6-K · 2024-11-12 · 0001654954-24-014085

2024-07-01 to 2024-09-30

—2,310,283
Source

6-K/A · 2024-08-19 · 0001654954-24-010915

2024-04-01 to 2024-06-30

———9,410,097
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

9,032,724
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

14,450,094
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD——————23,325
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

14,662
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

113,862
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

63,586
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

189,054
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

143,071
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD——————443,526
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

286,944
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

2,113,386
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

———
ProceedsFromIssuingSharesUSD——————0
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

296,437
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

338,331
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

10,670,618
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

34
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

0
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodUSD——————1,181,499
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

—1,181,499
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

-6,189,077
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

443,138
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

158,036
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD—————————0
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

0
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

250,000
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemQ4 2025Q4 2024Q3 2025Q3 2024Q2 2025Q2 2024Q1 2025Q1 2024FY 2025FY 2024FY 2023FY 2022
Selling, General and Administrative ExpenseUSD——3,041,374
Source

6-K · 2025-11-06 · 0001185185-25-001635

2025-07-01 to 2025-09-30

3,250,030
Source

6-K · 2025-11-06 · 0001185185-25-001635

2024-07-01 to 2024-09-30

3,313,275
Source

6-K · 2025-08-07 · 0001185185-25-000906

2025-04-01 to 2025-06-30

2,310,283
Source

6-K · 2025-08-07 · 0001185185-25-000906

2024-04-01 to 2024-06-30

1,328,111
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

1,919,212
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

9,047,918
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

———
Additional Financial Items
ApplicableTaxRatenumber————————0.27
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

0.27
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

0.27
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

0.27
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

DeferredTaxExpenseIncomeUSD——————————0
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

0
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

DepreciationAndAmortisationExpenseUSD——145,336
Source

6-K · 2025-11-06 · 0001185185-25-001635

2025-07-01 to 2025-09-30

120,814
Source

6-K · 2025-11-06 · 0001185185-25-001635

2024-07-01 to 2024-09-30

141,383
Source

6-K · 2025-08-07 · 0001185185-25-000906

2025-04-01 to 2025-06-30

136,813
Source

6-K · 2025-08-07 · 0001185185-25-000906

2024-04-01 to 2024-06-30

129,690
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

120,141
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

545,780
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

490,571
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

2,506,316
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

4,537,415
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

DepreciationRightofuseAssetsUSD———————————114,907
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD——996,194
Source

6-K · 2025-11-06 · 0001185185-25-001635

2025-07-01 to 2025-09-30

65,424
Source

6-K · 2025-11-06 · 0001185185-25-001635

2024-07-01 to 2024-09-30

849,584
Source

6-K · 2025-08-07 · 0001185185-25-000906

2025-04-01 to 2025-06-30

111,524
Source

6-K · 2025-08-07 · 0001185185-25-000906

2024-04-01 to 2024-06-30

291,272
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

57,743
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

2,945,502
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

152,214
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

3,835,475
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

1,531,258
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

FinanceCostsUSD——91,570
Source

6-K · 2025-11-06 · 0001185185-25-001635

2025-07-01 to 2025-09-30

10,371
Source

6-K · 2025-11-06 · 0001185185-25-001635

2024-07-01 to 2024-09-30

116,962
Source

6-K · 2025-08-07 · 0001185185-25-000906

2025-04-01 to 2025-06-30

8,357
Source

6-K · 2025-08-07 · 0001185185-25-000906

2024-04-01 to 2024-06-30

22,168
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

12,414
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

158,063
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

33,017
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

299
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

48,822
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

GeneralAndAdministrativeExpenseUSD———3,250,030
Source

6-K · 2024-11-12 · 0001654954-24-014085

2024-07-01 to 2024-09-30

—2,310,283
Source

6-K/A · 2024-08-19 · 0001654954-24-010915

2024-04-01 to 2024-06-30

———9,410,097
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

9,032,724
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

14,450,094
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

InterestExpenseUSD—————————9,343
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

24,288
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

149,906
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

InterestExpenseOnLeaseLiabilitiesUSD———————————19,062
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

OtherIncomeUSD——6,202
Source

6-K · 2025-11-06 · 0001185185-25-001635

2025-07-01 to 2025-09-30

0
Source

6-K · 2025-11-06 · 0001185185-25-001635

2024-07-01 to 2024-09-30

1,935,956
Source

6-K · 2025-08-07 · 0001185185-25-000906

2025-04-01 to 2025-06-30

0
Source

6-K · 2025-08-07 · 0001185185-25-000906

2024-04-01 to 2024-06-30

7,060
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

0
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

1,946,491
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

3,989
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

——
ProfessionalFeesExpenseUSD——735,946
Source

6-K · 2025-11-06 · 0001185185-25-001635

2025-07-01 to 2025-09-30

618,906
Source

6-K · 2025-11-06 · 0001185185-25-001635

2024-07-01 to 2024-09-30

1,602,570
Source

6-K · 2025-08-07 · 0001185185-25-000906

2025-04-01 to 2025-06-30

958,377
Source

6-K · 2025-08-07 · 0001185185-25-000906

2024-04-01 to 2024-06-30

355,722
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

858,423
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

3,278,735
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

3,074,130
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

3,248,233
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

5,208,356
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

ProfitLossAttributableToNoncontrollingInterestsUSD——-4,747,600
Source

6-K · 2025-11-06 · 0001185185-25-001635

2025-07-01 to 2025-09-30

-4,015,327
Source

6-K · 2025-11-06 · 0001185185-25-001635

2024-07-01 to 2024-09-30

-9,766,327
Source

6-K · 2025-08-07 · 0001185185-25-000906

2025-04-01 to 2025-06-30

-3,352,499
Source

6-K · 2025-08-07 · 0001185185-25-000906

2024-04-01 to 2024-06-30

-8,739,881
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

-2,091,425
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

-26,956,840
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

-14,915,529
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

-18,230,588
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

—
ProfitLossFromOperatingActivitiesUSD——-4,678,127
Source

6-K · 2025-11-06 · 0001185185-25-001635

2025-07-01 to 2025-09-30

-4,181,070
Source

6-K · 2025-11-06 · 0001185185-25-001635

2024-07-01 to 2024-09-30

-4,853,439
Source

6-K · 2025-08-07 · 0001185185-25-000906

2025-04-01 to 2025-06-30

-3,456,606
Source

6-K · 2025-08-07 · 0001185185-25-000906

2024-04-01 to 2024-06-30

-3,397,423
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

-2,257,356
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

-15,302,374
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

——-27,429,611
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

ResearchAndDevelopmentExpenseUSD——495,223
Source

6-K · 2025-11-06 · 0001185185-25-001635

2025-07-01 to 2025-09-30

744,802
Source

6-K · 2025-11-06 · 0001185185-25-001635

2024-07-01 to 2024-09-30

549,197
Source

6-K · 2025-08-07 · 0001185185-25-000906

2025-04-01 to 2025-06-30

897,986
Source

6-K · 2025-08-07 · 0001185185-25-000906

2024-04-01 to 2024-06-30

1,648,350
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2025-01-01 to 2025-03-31

160,260
Source

6-K/A · 2025-06-16 · 0001185185-25-000649

2024-01-01 to 2024-03-31

2,763,174
Source

20-F · 2026-03-26 · 0001185185-26-001069

2025-01-01 to 2025-12-31

6,083,378
Source

20-F/A · 2025-03-31 · 0001654954-25-003693

2024-01-01 to 2024-12-31

3,859,178
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

6,910,844
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

RevenueFromInterestUSD——————————568,919
Source

20-F · 2024-04-02 · 0001654954-24-004067

2023-01-01 to 2023-12-31

183,037
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

SellingExpenseUSD———————————616,002
Source

20-F · 2023-03-31 · 0001062993-23-008232

2022-01-01 to 2022-12-31

ProfitLossAttributableToOwnersOfParent————
Source

6-K · 2024-11-12 · 0001654954-24-014085

2024-07-01 to 2024-09-30

————————

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

qntmex99-1.htm · 6-K · 2026-11-12

Exhibit 99.1 Quantum Biopharma Ltd. (formerly, FSD Pharma Inc.) Condensed consolidated interim financial statements For the three and nine months ended September 30, 2026, and 2025 [expressed in United States dollars] QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION [unaudited] [expressed in United States dollars] As at September 30, …

6-K · 2026-11-12 · 0001185185-26-005323

Read attachment ↗
qntmex99-2.htm · 6-K · 2026-11-12

Exhibit 99.2 QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As used in this management’s discussion and analysis of financial condition and results of operations (this “MD&A”), unless the context indicates or requires otherwise, all references to the “Company”, “Quantum”, “Quantum BioPharma”, “we”, “us” or “our” refer to Quantum BioPharma Ltd., together with our subsidiaries, on a consolidated basis as …

6-K · 2026-11-12 · 0001185185-26-005323

Read attachment ↗
qntmex99-1.htm · 6-K · 2026-09-17

Exhibit 99.1 THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. QUANTUM BIOPHARMA PROVIDES CORPORATE UPDATE Toronto, Ontario - March 7, 2025 -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate…

6-K · 2026-09-17 · 0001185185-26-004098

Read attachment ↗
qntmex99-2.htm · 6-K · 2026-09-17

Exhibit 99.2 Quantum BioPharma Ltd. Announces Corporate Updates Toronto, Ontario - October 29, 2025 - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today anno…

6-K · 2026-09-17 · 0001185185-26-004098

Read attachment ↗
qntmex99-1.htm · 6-K · 2026-09-02

Exhibit 99.1 Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange Toronto, Ontario -- September 1, 2026 -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders…

6-K · 2026-09-02 · 0001185185-26-003794

Read attachment ↗
qntmex99-1.htm · 6-K · 2026-08-13

Exhibit 99.1 Quantum Biopharma Ltd. (formerly, FSD Pharma Inc.) Condensed consolidated interim financial statements For the three and six months ended June 30, 2026, and 2025 [expressed in United States dollars] QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION [unaudited] [expressed in United States dollars] As at June 30, December 31, …

6-K · 2026-08-13 · 0001185185-26-003497

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.